Lyle L Moldawer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6722310/publications.pdf

Version: 2024-02-01

416 papers 33,678 citations

93 h-index 166

426 all docs

426 docs citations

426 times ranked 32108 citing authors

g-index

#	Article	IF	CITATIONS
1	Chronic Critical Illness in Patients With Sepsis is Associated With Persistent Anemia, Inflammation, and Impaired Functional Outcomes. American Surgeon, 2023, 89, 2563-2571.	0.4	6
2	Older Adults Demonstrate Biomarker Evidence of the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) After Sepsis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 188-196.	1.7	17
3	Clinical Trajectories of Acute Kidney Injury in Surgical Sepsis. Annals of Surgery, 2022, 275, 1184-1193.	2.1	15
4	Influence of age and sex on microRNA response and recovery in the hippocampus following sepsis. Aging, 2022, 14, 728-746.	1.4	9
5	Ineffective Erythropoietin Response to Anemia in Sepsis. Surgical Infections, 2022, 23, 142-149.	0.7	4
6	Redefining critical illness. Nature Medicine, 2022, 28, 1141-1148.	15.2	136
7	Evaluation of a Multivalent Transcriptomic Metric for Diagnosing Surgical Sepsis and Estimating Mortality Among Critically Ill Patients. JAMA Network Open, 2022, 5, e2221520.	2.8	9
8	A Whole Blood Enzyme-Linked Immunospot Assay for Functional Immune Endotyping of Septic Patients. Journal of Immunology, 2021, 206, 23-36.	0.4	20
9	Transcriptomic responses from improved murine sepsis models can better mimic human surgical sepsis. FASEB Journal, 2021, 35, e21156.	0.2	5
10	The Effect of Aging Physiology on Critical Care. Critical Care Clinics, 2021, 37, 135-150.	1.0	9
11	A road map from single-cell transcriptome to patient classification for the immune response to trauma. JCl Insight, 2021, 6, .	2.3	29
12	Cecal Slurry Injection in Neonatal and Adult Mice. Methods in Molecular Biology, 2021, 2321, 27-41.	0.4	10
13	Severe Acute Respiratory Syndrome–Associated Coronavirus 2 Infection and Organ Dysfunction in the ICU: Opportunities for Translational Research. , 2021, 3, e0374.		20
14	Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness. Journal of Clinical Medicine, 2021, 10, 1693.	1.0	32
15	Dysregulated Immunity and Immunotherapy after Sepsis. Journal of Clinical Medicine, 2021, 10, 1742.	1.0	35
16	Lipid and lipoprotein predictors of functional outcomes and long-term mortality after surgical sepsis. Annals of Intensive Care, 2021, 11, 82.	2.2	9
17	The impact of sarcopenia and acute muscle mass loss on longâ€term outcomes in critically ill patients with intraâ€abdominal sepsis. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1203-1213.	2.9	38
18	Chronic critical illness after hypothermia in trauma patients. Trauma Surgery and Acute Care Open, 2021, 6, e000747.	0.8	1

#	Article	IF	Citations
19	Chronic Critical Illness Elicits a Unique Circulating Leukocyte Transcriptome in Sepsis Survivors. Journal of Clinical Medicine, 2021, 10, 3211.	1.0	5
20	Identification of unique microRNA expression patterns in bone marrow hematopoietic stem and progenitor cells after hemorrhagic shock and multiple injuries in young and old adult mice. Journal of Trauma and Acute Care Surgery, 2021, 91, 692-699.	1.1	0
21	Interleukin-7 Reverses Lymphopenia and Improves T-Cell Function in Coronavirus Disease 2019 Patient With Inborn Error of Toll-Like Receptor 3: A Case Report. , 2021, 3, e0500.		14
22	Biomarker Evidence of the Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) in Chronic Critical Illness (CCI) After Surgical Sepsis. Annals of Surgery, 2021, 274, 664-673.	2.1	21
23	A Novel Single Cell RNA-seq Analysis of Non-Myeloid Circulating Cells in Late Sepsis. Frontiers in Immunology, 2021, 12, 696536.	2.2	17
24	A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes. Critical Care, 2021, 25, 341.	2.5	17
25	Septic Stability? Gut Microbiota in Young Adult Mice Maintains Overall Stability After Sepsis Compared to Old Adult Mice. Shock, 2021, 55, 519-525.	1.0	12
26	Single-Cell RNA-seq of Human Myeloid-Derived Suppressor Cells in Late Sepsis Reveals Multiple Subsets With Unique Transcriptional Responses: A Pilot Study. Shock, 2021, 55, 587-595.	1.0	32
27	Distinct immunologic endotypes are associated with clinical trajectory after severe blunt trauma and hemorrhagic shock. Journal of Trauma and Acute Care Surgery, 2021, 90, 257-267.	1.1	14
28	A Transcriptomic Severity Metric That Predicts Clinical Outcomes in Critically III Surgical Sepsis Patients., 2021, 3, e0554.		17
29	Aluminum Adjuvant Improves Survival Via NLRP3 Inflammasome and Myeloid Non-Granulocytic Cells in a Murine Model of Neonatal Sepsis. Shock, 2021, 55, 274-282.	1.0	5
30	Reply to "Do Not Blame the Rodent for the Failure of Developing Sepsis Therapies― Shock, 2021, 56, 152-153.	1.0	1
31	Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis. Frontiers in Immunology, 2021, 12, 792448.	2.2	18
32	Effect of Beta-Blockade on the Expression of Regulatory MicroRNA after Severe Trauma and Chronic Stress. Journal of the American College of Surgeons, 2020, 230, 121-129.	0.2	8
33	Persistently increased cell-free DNA concentrations only modestly contribute to outcome and host response in sepsis survivors with chronic critical illness. Surgery, 2020, 167, 646-652.	1.0	9
34	Prospective Validation of a Transcriptomic Metric in Severe Trauma. Annals of Surgery, 2020, 271, 802-810.	2.1	26
35	Discovery and Validation of Urinary Molecular Signature of Early Sepsis. , 2020, 2, e0195.		9
36	Abdominal sepsis patients have a high incidence of chronic critical illness with dismal long-term outcomes. American Journal of Surgery, 2020, 220, 1467-1474.	0.9	17

#	Article	IF	Citations
37	Lipid intensive drug therapy for sepsis pilot: A Bayesian phase I clinical trial. Journal of the American College of Emergency Physicians Open, 2020, 1, 1332-1340.	0.4	7
38	Phenotypic heterogeneity by site of infection in surgical sepsis: a prospective longitudinal study. Critical Care, 2020, 24, 203.	2.5	29
39	Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respiratory Medicine, the, 2020, 8, 946-949.	5.2	111
40	Older Sepsis Survivors Suffer Persistent Disability Burden and Poor Longâ€Term Survival. Journal of the American Geriatrics Society, 2020, 68, 1962-1969.	1.3	36
41	Immunological Endotyping of Chronic Critical Illness After Severe Sepsis. Frontiers in Medicine, 2020, 7, 616694.	1.2	18
42	Abstract TMP91: Pre-Sepsis P-wave Terminal Force in Lead V1 (PTFV1) as a Predictor of Atrial Fibrillation, In-Hospital Mortality, and Cognition in Sepsis Patients. Stroke, 2020, 51, .	1.0	0
43	Premise for Standardized Sepsis Models. Shock, 2019, 51, 4-9.	1.0	41
44	Prognostic value of NT-proBNP levels in the acute phase of sepsis on lower long-term physical function and muscle strength in sepsis survivors. Critical Care, 2019, 23, 230.	2.5	17
45	Age and Sex Influence the Hippocampal Response and Recovery Following Sepsis. Molecular Neurobiology, 2019, 56, 8557-8572.	1.9	29
46	Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis. Critical Care, 2019, 23, 355.	2.5	64
47	Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Medicine, 2019, 45, 1360-1371.	3.9	117
48	Cell-free nuclear, but not mitochondrial, DNA concentrations correlate with the early host inflammatory response after severe trauma. Scientific Reports, 2019, 9, 13648.	1.6	23
49	Persistent inflammation and anemia among critically ill septic patients. Journal of Trauma and Acute Care Surgery, 2019, 86, 260-267.	1.1	20
50	Persistently Elevated Glucagon-Like Peptide-1 Levels among Critically Ill Surgical Patients after Sepsis and Development of Chronic Critical Illness and Dismal Long-Term Outcomes. Journal of the American College of Surgeons, 2019, 229, 58-67e1.	0.2	30
51	Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*. Critical Care Medicine, 2019, 47, 632-642.	0.4	149
52	Part I: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Study Design and Humane Modeling Endpoints. Shock, 2019, 51, 10-22.	1.0	57
53	LIPid Intensive Drug therapy for Sepsis Pilot (LIPIDS-P): Phase I/II clinical trial protocol of lipid emulsion therapy for stabilising cholesterol levels in sepsis and septic shock. BMJ Open, 2019, 9, e029348.	0.8	18
54	Old Mice Demonstrate Organ Dysfunction as well as Prolonged Inflammation, Immunosuppression, and Weight Loss in a Modified Surgical Sepsis Model*. Critical Care Medicine, 2019, 47, e919-e929.	0.4	27

#	Article	IF	Citations
55	The authors reply. Critical Care Medicine, 2019, 47, e788-e789.	0.4	O
56	What's New in Shock, February 2019?. Shock, 2019, 51, 143-146.	1.0	0
57	Current Epidemiology of Surgical Sepsis. Annals of Surgery, 2019, 270, 502-510.	2.1	60
58	A checkpoint on innate myeloid cells in pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-5.	0.8	9
59	MySurgeryRisk: Development and Validation of a Machine-learning Risk Algorithm for Major Complications and Death After Surgery. Annals of Surgery, 2019, 269, 652-662.	2.1	197
60	The impact of age on the innate immune response and outcomes after severe sepsis/septic shock in trauma and surgical intensive care unit patients. Journal of Trauma and Acute Care Surgery, 2018, 85, 247-255.	1.1	44
61	A community approach to mortality prediction in sepsis via gene expression analysis. Nature Communications, 2018, 9, 694.	5.8	178
62	Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients. Journal of Trauma and Acute Care Surgery, 2018, 84, 342-349.	1.1	91
63	Immunotherapy: It is not just for cancer anymore. Journal of Leukocyte Biology, 2018, 103, 9-11.	1.5	6
64	HDL Cholesterol Efflux is Impaired in Older Patients with Early Sepsis: A Subanalysis of a Prospective Pilot Study. Shock, 2018, 50, 66-70.	1.0	24
65	Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult. Current Opinion in Hematology, 2018, 25, 37-43.	1.2	49
66	Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis. Shock, 2018, 49, 249-258.	1.0	98
67	Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): An International Expert Consensus Initiative for Improvement of Animal Modeling in Sepsis. Shock, 2018, 50, 377-380.	1.0	141
68	Hyperacute Monocyte Gene Response Patterns Are Associated With Lower Extremity Vein Bypass Graft Failure. Circulation Genomic and Precision Medicine, 2018, 11, e001970.	1.6	4
69	Sepsis is associated with reduced spontaneous neutrophil migration velocity in human adults. PLoS ONE, 2018, 13, e0205327.	1.1	12
70	HDL inflammatory index correlates with and predicts severity of organ failure in patients with sepsis and septic shock. PLoS ONE, 2018, 13, e0203813.	1.1	40
71	Impact of toll-like receptor 4 stimulation on human neonatal neutrophil spontaneous migration, transcriptomics, and cytokine production. Journal of Molecular Medicine, 2018, 96, 673-684.	1.7	12
72	Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery. Surgery, 2018, 164, 178-184.	1.0	75

#	Article	IF	Citations
73	The Postinjury Inflammatory State and the Bone Marrow Response to Anemia. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 629-638.	2.5	32
74	Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy. Frontiers in Immunology, 2018, 9, 595.	2.2	119
75	Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome. Frontiers in Immunology, 2018, 9, 1511.	2.2	167
76	Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Infection, 2018, 46, 687-691.	2.3	28
77	Myeloid-Derived Suppressor Cells and Pulmonary Hypertension. International Journal of Molecular Sciences, 2018, 19, 2277.	1.8	5
78	Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Intensive Care Medicine Experimental, 2018, 6, 26.	0.9	61
79	Mouse Injury Model of Polytrauma and Shock. Methods in Molecular Biology, 2018, 1717, 1-15.	0.4	13
80	Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression After Severe Sepsis/Septic Shock. Annals of Surgery, 2017, 265, 827-834.	2.1	196
81	Microbial recognition and danger signals in sepsis and trauma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 2564-2573.	1.8	100
82	Pathogenesis of Diffuse Alveolar Hemorrhage in Murine Lupus. Arthritis and Rheumatology, 2017, 69, 1280-1293.	2.9	45
83	Persistent Inflammation, Immunosuppression and Catabolism Syndrome. Critical Care Clinics, 2017, 33, 245-258.	1.0	146
84	Sepsis Diagnostics. Critical Care Medicine, 2017, 45, 129-130.	0.4	1
85	LPS Stimulation of Cord Blood Reveals a Newborn-Specific Neutrophil Transcriptomic Response and Cytokine Production. Shock, 2017, 47, 606-614.	1.0	19
86	Murine Models of Sepsis and Trauma: Can We Bridge the Gap?. ILAR Journal, 2017, 58, 90-105.	1.8	119
87	Exploring the Predictive Ability of Dysfunctional High-Density Lipoprotein for Adverse Outcomes in Emergency Department Patients with Sepsis: A Preliminary Investigation. Shock, 2017, 48, 539-544.	1.0	20
88	Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome. Critical Care Medicine, 2017, 45, 253-262.	0.4	346
89	ICU-Acquired Weakness, Chronic Critical Illness, and the Persistent Inflammation-Immunosuppression and Catabolism Syndrome. Critical Care Medicine, 2017, 45, e1184.	0.4	7
90	The Epidemiology of Chronic Critical Illness After Severe Traumatic Injury at Two Level–One Trauma Centers*. Critical Care Medicine, 2017, 45, 1989-1996.	0.4	87

#	Article	IF	CITATIONS
91	Neutrophil chemotaxis and transcriptomics in term and preterm neonates. Translational Research, 2017, 190, 4-15.	2.2	41
92	Sepsis and Critical Illness Research Center investigators: protocols and standard operating procedures for a prospective cohort study of sepsis in critically ill surgical patients. BMJ Open, 2017, 7, e015136.	0.8	65
93	The role of NIGMS P50 sponsored team science in our understanding of multiple organ failure. Journal of Trauma and Acute Care Surgery, 2017, 83, 520-531.	1.1	12
94	The authors reply. Critical Care Medicine, 2017, 45, e740-e741.	0.4	0
95	Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Cancer Research, 2017, 77, 672-683.	0.4	24
96	Impact of Early-Life Exposures to Infections, Antibiotics, and Vaccines on Perinatal and Long-term Health and Disease. Frontiers in Immunology, 2017, 8, 729.	2.2	25
97	Immunological Defects in Neonatal Sepsis and Potential Therapeutic Approaches. Frontiers in Pediatrics, 2017, 5, 14.	0.9	65
98	Unique transcriptomic response to sepsis is observed among patients of different age groups. PLoS ONE, 2017, 12, e0184159.	1.1	40
99	Î ² -Blockade use for Traumatic Injuries and Immunomodulation. Shock, 2016, 46, 341-351.	1.0	46
100	What's New in Shock, September 2016?. Shock, 2016, 46, 227-229.	1.0	1
100	What's New in Shock, September 2016?. Shock, 2016, 46, 227-229. Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2627-35.	1.0 3.3	1 83
	Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proceedings of the National		
101	Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2627-35. Gene expression patterns in peripheral blood leukocytes in patients with recurrent ciguatera fish	3.3	83
101	Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2627-35. Gene expression patterns in peripheral blood leukocytes in patients with recurrent ciguatera fish poisoning: Preliminary studies. Harmful Algae, 2016, 57, 35-38.	3.3	83 5
101 102 103	Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2627-35. Gene expression patterns in peripheral blood leukocytes in patients with recurrent ciguatera fish poisoning: Preliminary studies. Harmful Algae, 2016, 57, 35-38. Sepsis and septic shock. Nature Reviews Disease Primers, 2016, 2, 16045. Sex-based differences in the genomic response, innate immunity, organ dysfunction, and clinical outcomes after severe blunt traumatic injury and hemorrhagic shock. Journal of Trauma and Acute	3.3 2.2 18.1	83 5 978
101 102 103	Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2627-35. Gene expression patterns in peripheral blood leukocytes in patients with recurrent ciguatera fish poisoning: Preliminary studies. Harmful Algae, 2016, 57, 35-38. Sepsis and septic shock. Nature Reviews Disease Primers, 2016, 2, 16045. Sex-based differences in the genomic response, innate immunity, organ dysfunction, and clinical outcomes after severe blunt traumatic injury and hemorrhagic shock. Journal of Trauma and Acute Care Surgery, 2016, 81, 478-485. Histological chorioamnionitis shapes the neonatal transcriptomic immune response. Early Human	3.3 2.2 18.1 1.1	83597827
101 102 103 104	Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2627-35. Gene expression patterns in peripheral blood leukocytes in patients with recurrent ciguatera fish poisoning: Preliminary studies. Harmful Algae, 2016, 57, 35-38. Sepsis and septic shock. Nature Reviews Disease Primers, 2016, 2, 16045. Sex-based differences in the genomic response, innate immunity, organ dysfunction, and clinical outcomes after severe blunt traumatic injury and hemorrhagic shock. Journal of Trauma and Acute Care Surgery, 2016, 81, 478-485. Histological chorioamnionitis shapes the neonatal transcriptomic immune response. Early Human Development, 2016, 98, 1-6.	3.3 2.2 18.1 1.1	8359782730

#	Article	IF	CITATIONS
109	Systemic inflammation as a predictor of clinical outcomes after lower extremity angioplasty/stenting. Journal of Vascular Surgery, 2016, 64, 766-778.e5.	0.6	13
110	The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. BMC Cancer, 2015, 15, 783.	1.1	37
111	Postnatal Age Is a Critical Determinant of the Neonatal Host Response to Sepsis. Molecular Medicine, 2015, 21, 496-504.	1.9	53
112	Cost and Mortality Associated With Postoperative Acute Kidney Injury. Annals of Surgery, 2015, 261, 1207-1214.	2.1	282
113	A Review of GM-CSF Therapy in Sepsis. Medicine (United States), 2015, 94, e2044.	0.4	83
114	A Detailed Characterization of the Dysfunctional Immunity and Abnormal Myelopoiesis Induced by Severe Shock and Trauma in the Aged. Journal of Immunology, 2015, 195, 2396-2407.	0.4	61
115	TRIF-Dependent Innate Immune Activation Is Critical for Survival to Neonatal Gram-Negative Sepsis. Journal of Immunology, 2015, 194, 1169-1177.	0.4	24
116	The future of murine sepsis and trauma research models. Journal of Leukocyte Biology, 2015, 98, 945-952.	1.5	89
117	Delayed emergency myelopoiesis following polymicrobial sepsis in neonates. Innate Immunity, 2015, 21, 386-391.	1.1	20
118	Improved emergency myelopoiesis and survival in neonatal sepsis by caspaseâ€1/11 ablation. Immunology, 2015, 145, 300-311.	2.0	34
119	Advanced age is associated with worsened outcomes and a unique genomic response in severely injured patients with hemorrhagic shock. Critical Care, 2015, 19, 77.	2.5	65
120	Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. Cancer Immunology, Immunotherapy, 2015, 64, 1553-1563.	2.0	25
121	Mice are not men. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E345.	3.3	102
122	Host Responses to Sepsis Vary in Different Low-Lethality Murine Models. PLoS ONE, 2014, 9, e94404.	1.1	39
123	HMGB1 as a therapeutic target for sepsis: it's all in the timing!. Expert Opinion on Therapeutic Targets, 2014, 18, 243-245.	1.5	52
124	Aged Mice Are Unable To Mount an Effective Myeloid Response to Sepsis. Journal of Immunology, 2014, 192, 612-622.	0.4	45
125	What's New in Shock, October 2014?. Shock, 2014, 42, 283-285.	1.0	0
126	Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma. Journal of Trauma and Acute Care Surgery, 2014, 76, 21-30.	1,1	145

#	Article	IF	CITATIONS
127	A Better Understanding of Why Murine Models of Trauma Do Not Recapitulate the Human Syndrome*. Critical Care Medicine, 2014, 42, 1406-1413.	0.4	41
128	A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections. JAMA Surgery, 2014, 149, 528.	2.2	73
129	Protective Immunity and Defects in the Neonatal and Elderly Immune Response to Sepsis. Journal of Immunology, 2014, 192, 3156-3165.	0.4	64
130	Parallels between Cancer and Infectious Disease. New England Journal of Medicine, 2014, 371, 380-383.	13.9	160
131	Novel Role for Tumor-Induced Expansion of Myeloid-Derived Cells in Cancer Cachexia. Journal of Immunology, 2014, 192, 6111-6119.	0.4	57
132	Is there value in plasma cytokine measurements in patients with severe trauma and sepsis?. Methods, 2013, 61, 3-9.	1.9	52
133	Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3507-3512.	3.3	2,518
134	Development of a Genomic Metric That Can Be Rapidly Used to Predict Clinical Outcome in Severely Injured Trauma Patients*. Critical Care Medicine, 2013, 41, 1175-1185.	0.4	88
135	Role of Innate Immunity in Neonatal Infection. American Journal of Perinatology, 2013, 30, 105-112.	0.6	128
136	Determination of Burn Patient Outcome by Large-Scale Quantitative Discovery Proteomics. Critical Care Medicine, 2013, 41, 1421-1434.	0.4	55
137	Maintenance of Anti-Sm/RNP Autoantibody Production by Plasma Cells Residing in Ectopic Lymphoid Tissue and Bone Marrow Memory B Cells. Journal of Immunology, 2013, 190, 3916-3927.	0.4	21
138	What's New in Shock? February 2013. Shock, 2013, 39, 117-120.	1.0	2
139	Acute kidney injury is associated with early cytokine changes after trauma. Journal of Trauma and Acute Care Surgery, 2013, 74, 1005-1013.	1.1	49
140	DAMPs, PAMPs, and the Origins of SIRS in Bacterial Sepsis. Shock, 2013, 39, 113-114.	1.0	62
141	Immediate postoperative inflammatory response predicts long-term outcome in lung-transplant recipients. Interactive Cardiovascular and Thoracic Surgery, 2012, 15, 603-607.	0.5	16
142	A regionalised strategy for improving motor vehicle-related highway driver deaths using a weighted averages method. Injury Prevention, 2012, 18, 16-21.	1.2	2
143	Monocyte Chemoattractant Protein-1/CCR2 Axis Promotes Vein Graft Neointimal Hyperplasia Through Its Signaling in Graft-Extrinsic Cell Populations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2418-2426.	1.1	22
144	Pleiotropic IFN-Dependent and -Independent Effects of IRF5 on the Pathogenesis of Experimental Lupus. Journal of Immunology, 2012, 188, 4113-4121.	0.4	53

#	Article	IF	CITATIONS
145	Persistent inflammation and immunosuppression. Journal of Trauma and Acute Care Surgery, 2012, 72, 1491-1501.	1.1	602
146	What Is the Role for the Inflammasome in Burn Injury and Sepsis?. Shock, 2012, 37, 124-125.	1.0	7
147	Benchmarking Outcomes in the Critically Injured Trauma Patient and the Effect of Implementing Standard Operating Procedures. Annals of Surgery, 2012, 255, 993-999.	2.1	92
148	The changing pattern and implications of multiple organ failure after blunt injury with hemorrhagic shock*. Critical Care Medicine, 2012, 40, 1129-1135.	0.4	139
149	Obese Patients Show a Depressed Cytokine Profile Following Severe Blunt Injury. Shock, 2012, 37, 253-256.	1.0	29
150	CXCR3 blockade: a novel anti-sepsis approach?. Critical Care, 2012, 16, 176.	2.5	1
151	Myeloid-derived suppressor cells in sepsis: friend or foe?. Intensive Care Medicine, 2012, 38, 928-930.	3.9	39
152	Microfluidics-based capture of human neutrophils for expression analysis in blood and bronchoalveolar lavage. Laboratory Investigation, 2011, 91, 1787-1795.	1.7	23
153	Early Blood Biomarkers Predict Organ Injury and Resource Utilization Following Complex Cardiac Surgery. Journal of Surgical Research, 2011, 168, 168-172.	0.8	12
154	A Paradoxical Role for Myeloid-Derived Suppressor Cells in Sepsis and Trauma. Molecular Medicine, 2011, 17, 281-292.	1.9	292
155	The Potential Influence of Common Viral Infections Diagnosed during Hospitalization among Critically III Patients in the United States. PLoS ONE, 2011, 6, e18890.	1.1	31
156	Mopeds and Scooters: Crash Outcomes in a High Traffic State. Journal of Trauma, 2011, 71, 217-222.	2.3	18
157	B cells enhance early innate immune responses during bacterial sepsis. Journal of Experimental Medicine, 2011, 208, 1673-1682.	4.2	144
158	A genomic storm in critically injured humans. Journal of Experimental Medicine, 2011, 208, 2581-2590.	4.2	1,040
159	Roles of Vaccinia Virus Genes E3L and K3L and Host Genes PKR and RNase L during Intratracheal Infection of C57BL/6 Mice. Journal of Virology, 2011, 85, 550-567.	1.5	49
160	Human transcriptome array for high-throughput clinical studies. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3707-3712.	3.3	122
161	Critical Role for CXC Ligand 10/CXC Receptor 3 Signaling in the Murine Neonatal Response to Sepsis. Infection and Immunity, 2011, 79, 2746-2754.	1.0	40
162	Superoxide Production by Macrophages and T Cells Is Critical for the Induction of Autoreactivity and Type 1 Diabetes. Diabetes, 2011, 60, 2144-2151.	0.3	85

#	Article	IF	Citations
163	Neutrophil Mobilization from the Bone Marrow during Polymicrobial Sepsis Is Dependent on CXCL12 Signaling. Journal of Immunology, 2011, 187, 911-918.	0.4	117
164	Sepsis Induces Early Alterations in Innate Immunity That Impact Mortality to Secondary Infection. Journal of Immunology, 2011, 186, 195-202.	0.4	137
165	Principles of wound healing. , 2011, , 423-450.		59
166	Incidence, Clinical Predictors, Genomics, and Outcome of Acute Kidney Injury Among Trauma Patients. Annals of Surgery, 2010, 252, 158-165.	2.1	122
167	Traditional Resuscitative Practices Fail to Resolve Metabolic Acidosis in Morbidly Obese Patients After Severe Blunt Trauma. Journal of Trauma, 2010, 68, 317-330.	2.3	27
168	Differences in outcome between obese and nonobese patients following severe blunt trauma are not consistent with an early inflammatory genomic response. Critical Care Medicine, 2010, 38, 51-58.	0.4	55
169	Do Tregs link sepsis to tumor growth?. Blood, 2010, 115, 4324-4325.	0.6	2
170	Clinical microfluidics for neutrophil genomics and proteomics. Nature Medicine, 2010, 16, 1042-1047.	15.2	168
171	Identification and Interpretation of Longitudinal Gene Expression Changes in Trauma. PLoS ONE, 2010, 5, e14380.	1.1	13
172	Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10. Journal of Experimental Medicine, 2010, 207, 319-326.	4.2	116
173	Analysis of factorial time-course microarrays with application to a clinical study of burn injury. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9923-9928.	3.3	62
174	Cutting Edge: Bacterial Infection Induces Hematopoietic Stem and Progenitor Cell Expansion in the Absence of TLR Signaling. Journal of Immunology, 2010, 184, 2247-2251.	0.4	112
175	Plasma Proteome Response to Severe Burn Injury Revealed by ¹⁸ O-Labeled "Universal― Reference-Based Quantitative Proteomics. Journal of Proteome Research, 2010, 9, 4779-4789.	1.8	54
176	Cecal Ligation and Puncture. Current Protocols in Immunology, 2010, 91, Unit 19.13.	3.6	47
177	A Genomic Score Prognostic of Outcome in Trauma Patients. Molecular Medicine, 2009, 15, 220-227.	1.9	104
178	Cancer-induced Expansion and Activation of CD11b+Gr-1+ Cells Predispose Mice to Adenoviral-triggered Anaphylactoid-type Reactions. Molecular Therapy, 2009, 17, 508-515.	3.7	18
179	A dynamic network of transcription in LPS-treated human subjects. BMC Systems Biology, 2009, 3, 78.	3.0	36
180	Major Hepatectomy Induces Phenotypic Changes in Circulating Dendritic Cells and Monocytes. Journal of Clinical Immunology, 2009, 29, 568-581.	2.0	10

#	Article	IF	CITATIONS
181	Large-Scale Multiplexed Quantitative Discovery Proteomics Enabled by the Use of an 18O-Labeled "Universal―Reference Sample. Journal of Proteome Research, 2009, 8, 290-299.	1.8	59
182	Magic bullets and surrogate biomarkers circa 2009*. Critical Care Medicine, 2009, 37, 1796-1798.	0.4	13
183	Impaired autophagy: A mechanism of mitochondrial dysfunction in anoxic rat hepatocytes. Hepatology, 2008, 47, 1725-1736.	3.6	175
184	Microfluidic Leukocyte Isolation for Gene Expression Analysis in Critically Ill Hospitalized Patients. Clinical Chemistry, 2008, 54, 891-900.	1.5	26
185	A Novel Type I IFN-Producing Cell Subset in Murine Lupus. Journal of Immunology, 2008, 180, 5101-5108.	0.4	110
186	Myeloidâ€Derived Suppressor Cells in Cancer Cachexia Syndrome: A New Explanation for an Old Problem. Journal of Parenteral and Enteral Nutrition, 2008, 32, 651-655.	1.3	18
187	Using innate immunity to characterize the host response to microbial invasion in severe sepsis. Future Microbiology, 2008, 3, 177-189.	1.0	7
188	Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. Blood, 2008, 112, 1750-1758.	0.6	158
189	ROLE OF TOLL-LIKE RECEPTORS IN THE DEVELOPMENT OF SEPSIS. Shock, 2008, 29, 315-321.	1.0	204
190	Opening the Window on Genome-wide Expression Analyses in Sepsis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 631-632.	2.5	1
191	Variable Requirement of Dendritic Cells for Recruitment of NK and T Cells to Different TLR Agonists. Journal of Immunology, 2007, 178, 3886-3892.	0.4	9
192	Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. Blood, 2007, 110, 3673-3681.	0.6	71
193	INCREASED MORTALITY AND ALTERED IMMUNITY IN NEONATAL SEPSIS PRODUCED BY GENERALIZED PERITONITIS. Shock, 2007, 28, 675-683.	1.0	127
194	Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: A potential clinical marker and mediator of severe sepsis*. Critical Care Medicine, 2007, 35, 387-392.	0.4	73
195	Stored Packed Red Blood Cell Transfusion Up-regulates Inflammatory Gene Expression in Circulating Leukocytes. Annals of Surgery, 2007, 246, 129-134.	2.1	63
196	MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis. Journal of Experimental Medicine, 2007, 204, 1463-1474.	4.2	581
197	Genomic and proteomic determinants of lower extremity revascularization failure: Rationale and study design. Journal of Vascular Surgery, 2007, 45, A82-A91.	0.6	9
198	In vivo adjuvant activity of the RNA component of the Sm/RNP lupus autoantigen. Arthritis and Rheumatism, 2007, 56, 3379-3386.	6.7	18

#	Article	IF	Citations
199	The Origins of Cachexia in Acute and Chronic Inflammatory Diseases*. Nutrition in Clinical Practice, 2006, 21, 68-81.	1.1	163
200	Increased Natural CD4+CD25+ Regulatory T Cells and Their Suppressor Activity Do Not Contribute to Mortality in Murine Polymicrobial Sepsis. Journal of Immunology, 2006, 177, 7943-7949.	0.4	121
201	Microfluidic Isolation of Leukocytes from Whole Blood for Phenotype and Gene Expression Analysis. Analytical Chemistry, 2006, 78, 5453-5461.	3.2	71
202	Cytokine Profile After Lung Transplantation: Correlation With Allograft Injury. Annals of Thoracic Surgery, 2006, 81, 1844-1850.	0.7	61
203	Differential toll-like receptor expression after ex vivo lipopolysaccharide exposure in patients with sepsis and following surgical stress. Clinical Immunology, 2006, 119, 180-187.	1.4	44
204	A critical role of CpG motifs in a murine peritonitis model by their binding to highly expressed toll-like receptor-9 on liver NKT cells. Journal of Hepatology, 2006, 45, 836-843.	1.8	36
205	Interleukin-18: A novel prognostic cytokine in bacteria-induced sepsis. Critical Care Medicine, 2006, 34, 1225-1233.	0.4	91
206	Interleukin-6: Still crazy after all these years*. Critical Care Medicine, 2006, 34, 2690-2691.	0.4	6
207	WHAT'S NEW IN SHOCK, AUGUST 2006. Shock, 2006, 26, 111-114.	1.0	1
208	Local thymic caspase-9 inhibition improves survival during polymicrobial sepsis in mice. Journal of Molecular Medicine, 2006, 84, 389-395.	1.7	23
209	Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNA. Immunology Letters, 2006, 107, 155-162.	1.1	22
210	Interleukin-6 and STAT3 protect the liver from hepatic ischemia and reperfusion injury during ischemic preconditioning. Surgery, 2006, 140, 793-802.	1.0	43
211	Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor α. Arthritis and Rheumatism, 2006, 54, 2872-2885.	6.7	31
212	WHAT'S NEW IN SHOCK, JUNE 2006?. Shock, 2006, 25, 555-556.	1.0	0
213	WHAT'S NEW IN Shock, January 2006?. Shock, 2006, 25, 1-3.	1.0	2
214	High Dynamic Range Characterization of the Trauma Patient Plasma Proteome. Molecular and Cellular Proteomics, 2006, 5, 1899-1913.	2.5	142
215	Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15564-15569.	3.3	106
216	dsRNA, but not other TLR agonists, induces both ILâ€8 and FNâ€Î² in human intestinal epithelial cells. FASEB Journal, 2006, 20, A200.	0.2	0

#	Article	IF	CITATIONS
217	Human leukocyte antigen expression in sepsis: What have we learned?*. Critical Care Medicine, 2005, 33, 236.	0.4	43
218	Delayed neutralization of interferon- \hat{l}^3 prevents lethality in primate Gram-negative bacteremic shock. Critical Care Medicine, 2005, 33, 797-805.	0.4	14
219	GENOME-WIDE MONOCYTIC mRNA EXPRESSION IN POLYTRAUMA PATIENTS FOR IDENTIFICATION OF CLINICAL OUTCOME. Shock, 2005, 24, 11-19.	1.0	38
220	NEUTROPHIL ELASTASE, MIP-2, AND TLR-4 EXPRESSION DURING HUMAN AND EXPERIMENTAL SEPSIS. Shock, 2005, 23, 39-44.	1.0	95
221	Biology of interleukin-10 and its regulatory roles in sepsis syndromes. Critical Care Medicine, 2005, 33, S468-S471.	0.4	121
222	Varying Blood Monocyte and Dendritic Cell Responses after Laparoscopic Versus Open Gastric Bypass Surgery. Obesity Surgery, 2005, 15, 1424-1431.	1.1	6
223	Splenic transposition is superior to caudal shunt as a model of murine total hepatic ischemia. Laboratory Investigation, 2005, 85, 90-98.	1.7	8
224	A network-based analysis of systemic inflammation in humans. Nature, 2005, 437, 1032-1037.	13.7	1,419
225	Adenoviral gene transfer of an NF-κB super-repressor increases collagen deposition in rodent cutaneous wound healing. Surgery, 2005, 138, 940-946.	1.0	12
226	A New Family of Synthetic Diterpenes that Regulates Cytokine Synthesis by Inhibiting lκBα Phosphorylation. ChemBioChem, 2005, 6, 133-144.	1.3	12
227	Comparative proteome analyses of human plasma followingin vivo lipopolysaccharide administration using multidimensional separations coupled with tandem mass spectrometry. Proteomics, 2005, 5, 572-584.	1.3	125
228	Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions. Journal of Leukocyte Biology, 2005, 78, 888-897.	1.5	77
229	Differential maturation of murine bone-marrow derived dendritic cells with lipopolysaccharide and tumor necrosis factor- $\hat{l}\pm$. Journal of Endotoxin Research, 2005, 11, 145-160.	2.5	20
230	Application of genome-wide expression analysis to human health and disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4801-4806.	3.3	238
231	CD11c+ Dendritic Cells Are Required for Survival in Murine Polymicrobial Sepsis. Journal of Immunology, 2005, 175, 3282-3286.	0.4	98
232	Quantitative Proteome Analysis of Human Plasma following in Vivo Lipopolysaccharide Administration Using 160/180 Labeling and the Accurate Mass and Time Tag Approach. Molecular and Cellular Proteomics, 2005, 4, 700-709.	2.5	156
233	Selective Activation of Peripheral Blood T Cell Subsets by Endotoxin Infusion in Healthy Human Subjects Corresponds to Differential Chemokine Activation. Journal of Immunology, 2005, 175, 6155-6162.	0.4	25
234	Functional Genomics and Gene Expression Profiling in Sepsis: Beyond Class Prediction. Clinical Infectious Diseases, 2005, 41, S427-S435.	2.9	31

#	Article	IF	CITATIONS
235	PRECLINICAL MODELS OF SHOCK AND SEPSIS: WHAT CAN THEY TELL US?. Shock, 2005, 24, 1-6.	1.0	102
236	Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock, 2005, 23, 488-93.	1.0	137
237	Functional modification of dendritic cells with recombinant adenovirus encoding interleukin 10 for the treatment of sepsis. Shock, 2005, 23, 507-15.	1.0	14
238	Genomic and Proteomic Determinants of Outcome in Patients Undergoing Thoracoabdominal Aortic Aneurysm Repair. Journal of Immunology, 2004, 172, 7103-7109.	0.4	61
239	Whole blood and leukocyte RNA isolation for gene expression analyses. Physiological Genomics, 2004, 19, 247-254.	1.0	186
240	Characterization of the Systemic Loss of Dendritic Cells in Murine Lymph Nodes During Polymicrobial Sepsis. Journal of Immunology, 2004, 173, 3035-3043.	0.4	119
241	Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression. Journal of Endotoxin Research, 2004, 10, 393-401.	2.5	8
242	Biology of tumor necrosis factor-alpha- implications for psoriasis. Experimental Dermatology, 2004, 13, 193-222.	1.4	175
243	Inducible nuclear factor-?B activation contributes to chemotherapy resistance in gastric cancer1, *1. Journal of the American College of Surgeons, 2004, 199, 249-258.	0.2	65
244	Continuous Flow Microfluidic Device for Rapid Erythrocyte Lysis. Analytical Chemistry, 2004, 76, 6247-6253.	3.2	112
245	Aberrant signaling in the TNFî \pm /TNF receptor 1 pathway of the NZM2410 lupus-prone mouse. Clinical Immunology, 2004, 110, 124-133.	1.4	13
246	Inhibition of NF-Kappa B augments sensitivity to 5-Fluorouracil/Folinic acid in colon cancer1. Journal of Surgical Research, 2004, 120, 178-188.	0.8	59
247	Cytokines and Wound Healing: The Role of Cytokine and Anticytokine Therapy in the Repair Response. Journal of Burn Care and Research, 2004, 25, 149-160.	1.7	114
248	INCREASED LYMPHOID TISSUE APOPTOSIS IN BABOONS WITH BACTEREMIC SHOCK. Shock, 2004, 21, 566-571.	1.0	37
249	CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)*. Critical Care Medicine, 2004, 32, 1100-1108.	0.4	68
250	Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls. Proceedings of the Nutrition Society, 2004, 63, 437-441.	0.4	37
251	Temporal patterns of gene expression in murine cutaneous burn wound healing. Physiological Genomics, 2004, 16, 341-348.	1.0	36
252	Gene Therapy for the Critically Ill Mouse. Basic Science for the Cardiologist, 2004, , 363-381.	0.1	0

#	Article	IF	Citations
253	Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3217-3221.	1.0	15
254	Anti-TNF-α therapies: the next generation. Nature Reviews Drug Discovery, 2003, 2, 736-746.	21.5	521
255	Molecular Characterization of the Acute Inflammatory Response to Infections with Gram-Negative versus Gram-Positive Bacteria. Infection and Immunity, 2003, 71, 5803-5813.	1.0	213
256	A Locus on Mouse Chromosome 6 That Determines Resistance to Herpes Simplex Virus Also Influences Reactivation, While an Unlinked Locus Augments Resistance of Female Mice. Journal of Virology, 2003, 77, 11661-11673.	1.5	74
257	Analysis of Gene Expression Patterns in Human Postburn Hypertrophic Scars. Journal of Burn Care and Research, 2003, 24, 371-377.	1.7	28
258	HYPOTHERMIA INDUCES INTERLEUKIN-10 AND ATTENUATES INJURY IN THE LUNGS OF ENDOTOXEMIC RATS. Shock, 2003, 20, 41-45.	1.0	32
259	ROLE OF ENDOGENOUS INTERLEUKIN-10 IN LOCAL AND DISTANT ORGAN INJURY AFTER VISCERAL ISCHEMIA-REPERFUSION. Shock, 2003, 20, 35-40.	1.0	45
260	Sepsis and the Dendritic Cell. Shock, 2003, 20, 386-401.	1.0	80
261	Blocking interleukin-18: A tumor necrosis factor-α lesson already learned *. Critical Care Medicine, 2003, 31, 2241-2242.	0.4	0
262	Genetic Polymorphisms, Functional Genomics and the Host Inflammatory Response to Injury and Inflammation. , 2003, 8, 15-37.		4
263	Structural Basis for the Proinflammatory Cytokine Activity of High Mobility Group Box 1. Molecular Medicine, 2003, 9, 37-45.	1.9	295
264	Activation of the Innate Immune Response in Critical Illness. , 2003, , 19-39.		0
265	Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Molecular Medicine, 2003, 9, 37-45.	1.9	148
266	Antineoplastic therapy in colorectal cancer through proteasome inhibition. American Surgeon, 2003, 69, 15-23.	0.4	15
267	Increased Survival in Sepsis by In Vivo Adenovirus-Induced Expression of IL-10 in Dendritic Cells. Journal of Immunology, 2002, 168, 3412-3418.	0.4	53
268	Direct Evidence for Tumor Necrosis Factor-α Signaling in Arteriogenesis. Circulation, 2002, 105, 1639-1641.	1.6	142
269	Bioglass?? Attenuates a Proinflammatory Response in Mouse Peritoneal Endotoxicosis. Shock, 2002, 17, 135-138.	1.0	20
270	Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Critical Care Medicine, 2002, 30, S58-S63.	0.4	247

#	Article	IF	CITATIONS
271	Interleukin-10 Fails to Modulate Low Shear Stress–Induced Neointimal Hyperplasia. Journal of Surgical Research, 2002, 102, 110-118.	0.8	14
272	PEAKS OF ENDOGENOUS G-CSF SERUM CONCENTRATIONS ARE FOLLOWED BY AN INCREASE IN RESPIRATORY BURST ACTIVITY OF GRANULOCYTES IN PATIENTS WITH SEPTIC SHOCK. Cytokine, 2002, 17, 275-284.	1.4	29
273	Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics, 2002, 140, 439-444.	0.9	60
274	Pro- and antiinflammatory cytokine production after radiofrequency ablation of unresectable hepatic tumors. Journal of the American College of Surgeons, 2002, 195, 774-781.	0.2	50
275	Humoral products from tumor necrosis factor-α–stimulated neutrophils suppress neutrophil function: Shedding new light on paracrine signaling*. Critical Care Medicine, 2002, 30, 716-717.	0.4	O
276	Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Critical Care Medicine, 2002, 30, S58-S63.	0.4	14
277	URINARY CYTOKINES FOR ASSESSING INFLAMMATION IN HIV-ASSOCIATED WASTING. Cytokine, 2001, 13, 305-313.	1.4	8
278	Nuclear factor-l ^o B is upregulated in colorectal cancer. Surgery, 2001, 130, 363-369.	1.0	261
279	Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon. Journal of Applied Physiology, 2001, 91, 2213-2223.	1.2	16
280	Apoptosis in sepsis: a new target for therapeutic exploration. FASEB Journal, 2001, 15, 879-892.	0.2	54
281	SEPSIS SYNDROMES: UNDERSTANDING THE ROLE OF INNATE AND ACQUIRED IMMUNITY. Shock, 2001, 16, 83-96.	1.0	422
282	CD64 surface expression on neutrophils is transiently upregulated in patients with septic shock. Intensive Care Medicine, 2001, 27, 1848-1852.	3.9	38
283	Considering immunomodulatory therapies in the septic patient: should apoptosis be a potential therapeutic target?. Immunology Letters, 2001, 75, 221-224.	1.1	27
284	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysisâ€f Patients?. Seminars in Dialysis, 2001, 13, 171-173.	0.7	1
285	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysisâ€f Patients?. Seminars in Dialysis, 2001, 13, 163-164.	0.7	105
286	Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 11503-11508.	3.3	112
287	Adenoviral Delivery of Human and Viral IL-10 in Murine Sepsis. Journal of Immunology, 2001, 167, 1053-1059.	0.4	40
288	Apoptosis in sepsis: a new target for therapeutic exploration. FASEB Journal, 2001, 15, 879-892.	0.2	245

#	Article	IF	CITATIONS
289	Gene Therapy Applications for the Treatment of Acute Inflammatory Conditions. , 2001, , 225-246.		O
290	Cytokine Biology. , 2001, , 933-947.		0
291	LAPAROTOMY PREVENTS LETHAL ENDOTOXEMIA IN A MURINE SEQUENTIAL INSULT MODEL BY AN IL-10-DEPENDENT MECHANISM. Shock, 2000, 14, 157-162.	1.0	10
292	Glucocorticoid and Fas Ligand Induced Mucosal Lymphocyte Apoptosis after Burn Injury. Journal of Trauma, 2000, 49, 710-716.	2.3	47
293	Tumor necrosis factor-α and the development of multiple organ failure. Critical Care Medicine, 2000, 28, 2158.	0.4	2
294	The relationship between visceral ischemia, proinflammatory cytokines, and organ injury in patients undergoing thoracoabdominal aortic aneurysm repair. Critical Care Medicine, 2000, 28, 3191-3197.	0.4	151
295	ANTICYTOKINE THERAPIES FOR ACUTE INFLAMMATION AND THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: IL-10 AND ISCHEMIA/REPERFUSION INJURY AS A NEW PARADIGM. Shock, 2000, 13, 425-434.	1.0	63
296	Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Repair and Regeneration, 2000, 8, 547-553.	1.5	60
297	Cytokine signaling-regulation of the immune response in normal and critically ill states. Critical Care Medicine, 2000, 28, N3-N12.	0.4	216
298	Lipopolysaccharide and $<$ scp>d $<$ /scp>-galactosamine-induced hepatic injury is mediated by TNF- $\hat{l}\pm$ and not by Fas ligand. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 278, R1196-R1201.	0.9	97
299	Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 278, R824-R830.	0.9	29
300	Glucocorticoid-induced, caspase-dependent organ apoptosis early after burn injury. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 278, R1005-R1018.	0.9	69
301	LPS-induced liver injury in <scp>d</scp> -galactosamine-sensitized mice requires secreted TNF-α and the TNF-p55 receptor. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 278, R1202-R1209.	0.9	149
302	Reduced Susceptibility of Nonobese Diabetic Mice to TNF-α and <scp>d</scp> -Galactosamine-Mediated Hepatocellular Apoptosis and Lethality. Journal of Immunology, 2000, 165, 6559-6567.	0.4	31
303	TNF- $\hat{l}\pm$ Receptor Signaling and IL-10 Gene Therapy Regulate the Innate and Humoral Immune Responses to Recombinant Adenovirus in the Lung. Journal of Immunology, 2000, 164, 443-451.	0.4	70
304	Direct Evidence for Cytokine Involvement in Neointimal Hyperplasia. Circulation, 2000, 102, 1697-1702.	1.6	170
305	Autoregulation of Human Monocyte-Derived Dendritic Cell Maturation and IL-12 Production by Cyclooxygenase- 2-Mediated Prostanoid Production. Journal of Immunology, 2000, 165, 4298-4304.	0.4	67
306	The Induction of EAE Is Only Partially Dependent on TNF Receptor Signaling but Requires the IL-1 Type I Receptor. Clinical Immunology, 2000, 95, 117-123.	1.4	79

#	Article	IF	CITATIONS
307	Neither Fas Ligand nor Endotoxin Is Responsible for Inducible Peritoneal Phagocyte Apoptosis during Sepsis/Peritonitis. Journal of Surgical Research, 2000, 91, 147-153.	0.8	26
308	Emerging Evidence of a More Complex Role for Proinflammatory and Antiinflammatory Cytokines in the Sepsis Response., 2000,, 145-154.		1
309	Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 277, R850-R855.	0.9	53
310	Granulocyte Colony-Stimulating Factor to Prevent the Progression of Systemic Nonresponsiveness in Systemic Inflammatory Response Syndrome and Sepsis. Blood, 1999, 93, 425-439.	0.6	64
311	Discordant tumor necrosis factor- \hat{l}_{\pm} superfamily gene expression in bacterial peritonitis and endotoxemic shock. Surgery, 1999, 126, 349-357.	1.0	29
312	Attenuation of skeletal muscle ischemia/reperfusion injury by inhibition of tumor necrosis factor. Journal of Vascular Surgery, 1999, 29, 370-376.	0.6	61
313	Products of Cyclooxygenase-2 Catalysis Regulate Postoperative Bowel Motility. Journal of Surgical Research, 1999, 86, 50-54.	0.8	48
314	Characterization in Vitro and in Vivo of Hammerhead Ribozymes Directed against Murine Tumor Necrosis Factorα. Biochemical and Biophysical Research Communications, 1999, 260, 390-397.	1.0	5
315	APPLICATION OF GENE THERAPY TO ACUTE INFLAMMATORY DISEASES. Shock, 1999, 12, 83-101.	1.0	17
316	Caspase-3–Dependent Organ Apoptosis Early After Burn Injury. Annals of Surgery, 1999, 229, 851.	2.1	60
317	Organ apoptosis in the septic patient. Critical Care Medicine, 1999, 27, 1381-1382.	0.4	20
318	Granulocyte Colony-Stimulating Factor to Prevent the Progression of Systemic Nonresponsiveness in Systemic Inflammatory Response Syndrome and Sepsis. Blood, 1999, 93, 425-439.	0.6	27
319	Cationic liposome-mediated gene transfer during acute pancreatitis: tissue specificity, duration, and effects of acute inflammation,. Journal of Gastrointestinal Surgery, 1998, 2, 95-101.	0.9	5
320	Leptin and ciliary neurotropic factor (CNTF) inhibit fasting-induced suppression of luteinizing hormone release in rats: role of neuropeptide Y. Neuroscience Letters, 1998, 240, 45-49.	1.0	76
321	The metabolic effects of pokeweek mitogen in mice. Metabolism: Clinical and Experimental, 1998, 47, 75-82.	1.5	3
322	Metalloproteinase inhibitors and wound healing: A novel enhancer of wound strength. Surgery, 1998, 124, 464-470.	1.0	103
323	Enhanced Collagen Accumulation Following Direct Transfection of the Inducible Nitric Oxide Synthase Gene in Cutaneous Wounds. Biochemical and Biophysical Research Communications, 1998, 246, 654-659.	1.0	141
324	INTERLEUKIN 6, BUT NOT CILIARY NEUROTROPHIC FACTOR OR LEUKAEMIA INHIBITORY FACTOR, IS RESPONSIBLE FOR THE ACUTE PHASE RESPONSE TO TURPENTINE-INDUCED MYOSITIS. Cytokine, 1998, 10, 452-456.	1.4	18

#	Article	IF	CITATIONS
325	Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. Journal of Applied Physiology, 1998, 84, 1119-1130.	1.2	33
326	Leptin produces anorexia and weight loss without inducing an acute phase response or protein wasting. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 274, R1518-R1525.	0.9	8
327	Transfection of the Type II TGF \hat{l}^2 Receptor Into Colon Cancer Cells Increases Receptor Expression, Inhibits Cell Growth, and Reduces the Malignant Phenotype. Annals of Surgery, 1998, 227, 781-789.	2.1	23
328	Transient Human Gene Therapy. Annals of Surgery, 1998, 227, 812-820.	2.1	24
329	Role of cytokines in the metabolic response to stress. Current Opinion in Clinical Nutrition and Metabolic Care, 1998, 1, 187-190.	1.3	7
330	Increased Leptin Expression in Mice with Bacterial Peritonitis is Partially Regulated by Tumor Necrosis Factor Alpha. Infection and Immunity, 1998, 66, 1800-1802.	1.0	68
331	A MATRIX METALLOPROTEINASE INHIBITOR PREVENTS PROCESSING OF TUMOR NECROSIS FACTOR \hat{l}_{\pm} (TNF \hat{l}_{\pm}) AN ABROGATES ENDOTOXIN-INDUCED LETHALITY. Shock, 1997, 7, 427-431.	1 <u>D</u> .o	76
332	Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor–dependent murine model of acute visceral ischemia. Journal of Vascular Surgery, 1997, 26, 113-118.	0.6	54
333	Nitric Oxide Contributes to Adriamycin's Antitumor Effect. Journal of Surgical Research, 1997, 69, 283-287.	0.8	40
334	Exogenous Human Recombinant Interleukin-10 Attenuates Hindlimb Ischemia–Reperfusion Injury. Journal of Surgical Research, 1997, 69, 425-428.	0.8	51
335	Evidence that brief stress may induce the acute phase response in rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1997, 273, R1998-R2004.	0.9	56
336	Inhibition of transforming growth factor alpha stimulation of human squamous cell carcinoma of the head and neck with anti-TGF- \hat{l}_{\pm} antibodies and tyrphostin. Annals of Surgical Oncology, 1997, 4, 670-684.	0.7	7
337	Proinflammatory cytokines, nutritional support, and the cachexia syndrome. Cancer, 1997, 79, 1828-1839.	2.0	179
338	Proinflammatory cytokines, nutritional support, and the cachexia syndrome. Cancer, 1997, 79, 1828-1839.	2.0	5
339	Hepatic tumor necrosis factors production and distant organ dysfunction in a murine model of obstructive jaundice. American Journal of Surgery, 1996, 171, 202-206.	0.9	34
340	Tumor Cell Nitric Oxide Inhibits Cell Growthin Vitro, but Stimulates Tumorigenesis and Experimental Lung Metastasisin Vivo. Journal of Surgical Research, 1996, 63, 49-52.	0.8	91
341	VISCERAL ISCHEMIA-REPERFUSION INJURY PROMOTES TUMOR NECROSIS FACTOR (TNF) AND INTERLEUKIN-1 (IL-1) DEPENDENT ORGAN INJURY IN THE MOUSE. Shock, 1996, 6, 171-176.	1.0	19
342	A Role for Tumor Necrosis Factor- \hat{l}_{\pm} in the Increased Mortality Associated with Vibrio Vulnificus Infection in the Presence of Hepatic Dysfunction. Annals of Surgery, 1996, 223, 428-433.	2.1	33

#	Article	IF	Citations
343	Visceral Ischemia and Organ Dysfunction After Thoracoabdominal Aortic Aneurysm Repair. Annals of Surgery, 1996, 223, 729-736.	2.1	61
344	VISCERAL ISCHEMIA-REPERFUSION INJURY PROMOTES TUMOR NECROSIS FACTOR (TNF) AND INTERLEUKIN-1 (IL-1) DEPENDENT ORGAN INJURY IN THE MOUSE. Shock, 1996, 6, 171-176.	1.0	49
345	BLOCKADE OF TUMOR NECROSIS FACTOR REDUCES LIPOPOLYSACCHARIDE LETHALITY, BUT NOT THE LETHALITY OF CECAL LIGATION AND PUNCTURE. Shock, 1995, 4, 89-95.	1.0	150
346	INTERLEUKIN-1 AND INTERLEUKIN-1 ANTAGONISM IN SEPSIS, SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, AND SEPTIC SHOCK. Shock, 1995, 3, 235-251.	1.0	144
347	Colon Cancer Cells That Are Not Growth Inhibited by TGF- \hat{l}^2 Lack Functional Type I and Type II TGF- \hat{l}^2 Receptors. Annals of Surgery, 1995, 221, 767-777.	2.1	27
348	Cytokine-mediated alterations in host metabolism prevent nutritional repletion in cachectic cancer patients. Journal of Surgical Oncology, 1995, 58, 77-82.	0.8	80
349	Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses Journal of Experimental Medicine, 1995, 181, 2289-2293.	4.2	115
350	Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response. Cytokine, 1995, 7, 510-516.	1.4	31
351	The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. Journal of Clinical Immunology, 1994, 14, 120-133.	2.0	28
352	Interleukin-1, interleukin-1 receptor, and interleukin-1 receptor antagonist. Proceedings of the Nutrition Society, 1994, 53, 393-400.	0.4	8
353	Anti-Endotoxin Therapy in Primate Bacteremia with HA-1A and BPI. Annals of Surgery, 1994, 220, 77-85.	2.1	37
354	Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. European Journal of Immunology, 1993, 23, 1889-1894.	1.6	148
355	Thermogenesis secondary to transdermal water loss causes growth retardation in essential fatty acid-deficient rats. Metabolism: Clinical and Experimental, 1993, 42, 1022-1026.	1.5	14
356	The Role of the Adrenals in the Acute Phase Response to Interleukin-1 and Tumor Necrosis Factor- \hat{l}_{\pm} . Journal of Surgical Research, 1993, 54, 70-78.	0.8	20
357	Modulation of Cytokine Responses in Sepsis. Annals of the New York Academy of Sciences, 1993, 685, 471-482.	1.8	4
358	Comparison of Peripheral Blood Leukocyte Kinetics After Live Escherichia coli, Endotoxin, or Interleukin-1 α Administration Studies Using a Novel Interleukin-1 Receptor Antagonist. Annals of Surgery, 1993, 218, 79-90.	2.1	30
359	Interleukin-1 TNFα and Their Naturally Occurring Antagonists in Sepsis. Blood Purification, 1993, 11, 128-133.	0.9	37
360	Tumor Necrosis Factor as a Mediator of Sepsis. , 1993, , 3-17.		2

#	Article	IF	CITATIONS
361	Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4845-4849.	3.3	809
362	Review: Experimental and Clinical Applications of Molecular Cell Biology in Nutrition and Metabolism. Journal of Parenteral and Enteral Nutrition, 1992, 16, 477-486.	1.3	3
363	The Role of Cytokines in Cancer Cachexia. Journal of Parenteral and Enteral Nutrition, 1992, 16, 43S-49S.	1.3	82
364	Impact of exogenous growth hormone on host preservation and tumor cell-cycle distribution in a rat sarcoma model. Journal of Surgical Research, 1991, 51, 99-105.	0.8	22
365	A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 1651-1655.	3.3	362
366	Pretranslational regulation of albumin synthesis in tumor-bearing mice. Gastroenterology, 1991, 100, 938-945.	0.6	21
367	Interleukin 1 receptor blockade attenuates the host inflammatory response Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4966-4970.	3.3	197
368	Tumor necrosis factor- \hat{l} ± and interleukin- $1\hat{l}$ ± production in cachectic, tumor-bearing mice. International Journal of Cancer, 1990, 46, 889-896.	2.3	47
369	Nutrition and Immunology: Challenge for the 1990s. Nutrition in Clinical Practice, 1990, 5, 187-188.	1.1	1
370	Glutamine or Fiber Supplementation of a Defined Formula Diet: Impact on Bacterial Translocation, Tissue Composition, and Response to Endotoxin. Journal of Parenteral and Enteral Nutrition, 1990, 14, 335-343.	1.3	86
371	Effect of prostaglandin E in multiple experimental models. IV. Effect on resistance to endotoxin and tumor necrosis factor shock. Journal of Surgical Research, 1990, 49, 328-332.	0.8	20
372	Increased degradation of albumin in cancer is not due to conformational or chemical modifications in the albumin molecule. Journal of Surgical Research, 1990, 49, 23-29.	0.8	16
373	The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans Journal of Clinical Investigation, 1990, 85, 1896-1904.	3.9	354
374	Anticachectin/tumor necrosis factorâ€Î± antibodies attenuate development of cachexia in tumor models. FASEB Journal, 1989, 3, 1956-1962.	0.2	205
375	Cachectin/tumor necrosis factorâ€Î± alters red blood cell kinetics and induces anemia in vivo. FASEB Journal, 1989, 3, 1637-1643.	0.2	213
376	Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia Journal of Experimental Medicine, 1989, 170, 1627-1633.	4.2	678
377	Starvation leads to decreased levels of mRNA for myofibrillar proteins. Journal of Surgical Research, 1989, 46, 457-461.	0.8	21
378	Hepatocellular membrane function during chronic burn injury. Journal of Surgical Research, 1989, 46, 311-316.	0.8	11

#	Article	IF	CITATIONS
379	Cachectin/tumor necrosis factor production by fetal and newborn rat hepatic macrophages. Journal of Pediatric Surgery, 1989, 24, 34-38.	0.8	15
380	Total Parenteral Nutrition and Bowel Rest Modify the Metabolic Response to Endotoxin in Humans. Annals of Surgery, 1989, 210, 449-457.	2.1	251
381	Interleukinâ€1 and Interleukinâ€6 Synergize to Increase Plasma Amyloid P and C3 Concentrations in the Mouse ^a . Annals of the New York Academy of Sciences, 1989, 557, 528-531.	1.8	4
382	Short-term effects of an intravenous infusion of a nutrient solution containing amino acids, glucose and insulin on leucine turnover and amino acid metabolism in patients with liver failure. Journal of Hepatology, 1988, 6, 101-108.	1.8	14
383	Appearance of hybridoma growth factor/interleukin-6 in the serum of mice bearing a methylcholanthrene-induced sarcoma. Biochemical and Biophysical Research Communications, 1988, 157, 575-579.	1.0	36
384	Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties Journal of Experimental Medicine, 1988, 167, 570-581.	4.2	545
385	Interleukin 1, tumour necrosis factorâ€elpha (cachectin) and the pathogenesis of cancer cachexia. Clinical Physiology, 1987, 7, 263-274.	0.7	121
386	Complications associated with the overfeeding of infected animals. Journal of Surgical Research, 1986, 40, 152-158.	0.8	23
387	Stimulatory effect of interleukin-1 upon hepatic metabolism. Metabolism: Clinical and Experimental, 1986, 35, 419-424.	1.5	70
388	Effect of DL-3-Hydroxybutyrate Infusions on Leucine and Glucose Kinetics in Burned Rats Receiving TPN. Journal of Nutrition, 1986, 116, 149-156.	1.3	3
389	Evaluation of the Protein Quality of Diets Containing Medium- and Long-Chain Triglyceride in Healthy Rats. Journal of Nutrition, 1986, 116, 343-349.	1.3	14
390	Short-term administration of parenteral glucose-lipid mixtures improves protein kinetics in portacaval shunted rats. Gastroenterology, 1986, 91, 305-312.	0.6	15
391	Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia: A prospective randomized crossover trial. Cancer, 1986, 58, 147-157.	2.0	103
392	The effects of high intensity exercise on muscle and plasma levels of alpha-ketoisocaproic acid. European Journal of Applied Physiology and Occupational Physiology, 1986, 55, 482-485.	1.2	20
393	Improvements in Host Immunity by Partially Purified Interleukin 1 in Rats with Portacaval Anastomosis and Splenectomy. Journal of Parenteral and Enteral Nutrition, 1986, 10, 146-150.	1.3	4
394	Report of a Research Workshop: Branchedâ€Chain Amino Acids in Stress and Injury. Journal of Parenteral and Enteral Nutrition, 1986, 10, 446-452.	1.3	73
395	Abnormal phenylalanine hydroxylation and tyrosine oxidation in a patient with acute fulminant liver disease with correction by liver transplantation. Gastroenterology, 1985, 89, 659-663.	0.6	28
396	Lipid emulsions and reticuloendothelial system function in healthy and burned guinea pigs. American Journal of Clinical Nutrition, 1985, 42, 855-863.	2,2	127

#	Article	IF	CITATIONS
397	The Effect of Lipid Emulsions on Reticuloendothelial System Function in the Injured Animal. Journal of Parenteral and Enteral Nutrition, 1985, 9, 559-565.	1.3	155
398	Xylitol, an Energy Source for Intravenous Nutrition after Trauma. Journal of Parenteral and Enteral Nutrition, 1985, 9, 199-209.	1.3	78
399	Branched chain amino acid enriched elemental diets support hepatic protein synthesis in injured rats. Nutrition Research, 1985, 5, 737-748.	1.3	4
400	Protein Dynamics during Refeeding of Protein-Depleted Rats: Effects of Increasing Amino Acid Intake by TPN or Enteral Continuous Feeding. Journal of Nutrition, 1984, 114, 75-88.	1.3	20
401	In Vitro Leukocyte Endogenous Mediator Production Is Not Impaired following Surgical Stress in Moderately Malnourished Patients. Journal of Parenteral and Enteral Nutrition, 1984, 8, 174-177.	1.3	3
402	Hypocaloric Lipid Emulsions and Amino Acid Metabolism in Injured Rats. Journal of Parenteral and Enteral Nutrition, 1984, 8, 361-366.	1.3	36
403	A rationale for administering leukocyte endogenous mediator to protein malnourished, hospitalized patients. Journal of Theoretical Biology, 1984, 106, 119-133.	0.8	4
404	Terminal transferase in patients hospitalized for malnutrition. Nutrition Research, 1984, 4, 237-244.	1.3	0
405	Protein metabolism during total parenteral nutrition (TPN) in injured rats using medium-chain triglycerides. Metabolism: Clinical and Experimental, 1984, 33, 901-909.	1.5	70
406	Structured medium-chain and long-chain triglyceride emulsions are superior to physical mixtures in sparing body protein in the burned rat. Metabolism: Clinical and Experimental, 1984, 33, 910-915.	1.5	112
407	Leukocyte endogenous mediator alters protein dynamics in rats. Metabolism: Clinical and Experimental, 1983, 32, 654-660.	1.5	63
408	Alterations in Tyrosine and Protein Kinetics Produced by Injury and Branched Chain Amino Acid Administration in Rats. Clinical Science, 1983, 64, 321-331.	1.8	27
409	Amino Acid and Protein Metabolism in Hospitalized Patients as Measured by I-[U-14C]Tyrosine and I-[1-14C]Leucine. Clinical Science, 1983, 65, 499-505.	1.8	10
410	Plasma Amino Acid Concentrations during Branched-chain Amino Acid Infusions In Stressed Patients. Journal of Trauma, 1982, 22, 747-752.	2.3	15
411	Effect of leukocyte endogenous mediator(s) on insulin and substrate profiles in the fasted rat. Journal of Surgical Research, 1982, 33, 151-157.	0.8	18
412	The influence of intravenous nutrition on protein dynamics following surgery. Metabolism: Clinical and Experimental, 1981, 30, 1150-1158.	1.5	78
413	Factors Determining the Preservation of Protein Status during Dietary Protein Deprivation. Journal of Nutrition, 1981, 111, 1287-1296.	1.3	14
414	Biological measures for the formulation of a hospital prognostic index. American Journal of Clinical Nutrition, 1981, 34, 2013-2022.	2.2	212

#	Article	IF	CITATIONS
415	In vivo demonstration of nitrogen-sparing mechanisms for glucose and amino acids in the injured rat. Metabolism: Clinical and Experimental, 1980, 29, 173-180.	1.5	89
416	A protein sparing model in the rat during hypocaloric feeding: Factors determining preservation of visceral protein function. Journal of Surgical Research, 1978, 25, 424-432.	0.8	10